Velocity Pharmaceutical Development LLC inked a licensing deal to pursue a drug development program with San Diego-based EuMederis Pharmaceuticals Inc.
Under the agreement, San Francisco-based Velocity will use the seed-stage biotechnology firm's EuPort technology for optimizing the pharmaceutical properties of peptide drugs.
Research and further development is being funded and carried out through special purpose development company Spitfire Pharma Inc.
The program will be managed by members of the Velocity team and by John Nestor, Ph.D., CEO of EuMederis.
Peptide hormones control a host of critical functions throughout the body. Peptide drugs, however, typically have a short duration of action and require self-injection, thus limiting their utility.
Recent advances in the design, synthesis and delivery of peptides, such as the EuPort technology, have increased interest in this attractive pharmaceutical class.
Terms of the deal are unannounced at this time.
La Jolla Pharmaceutical expands team
Sanford-Burnham's CEO resigns
Ligand receives equity milestone payment from Retrophin
BioMarin buys Zacharon in $10 million deal
Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.
SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.
All contents herein copyright San Diego Source ® 1994-2016